Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CBST

Cubist Pharmaceuticals (CBST) Stock Price, News & Analysis

Cubist Pharmaceuticals logo

About Cubist Pharmaceuticals Stock (NASDAQ:CBST)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive CBST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cubist Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CBST Stock News Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we drive, deliver packages, and even perform surgeries. According to Forbes, this could unlock a massive $24 trillion opportunity for investors. And I've zeroed in on 6 robotics stocks at the center of it all.
Key facts about Cubism
CBST:CA The Cannabist Company Holdings Inc.
What is Cubism?
Cubist Stock Hits New 52-Week High (CBST)
See More Headlines

CBST Stock Analysis - Frequently Asked Questions

Cubist Pharmaceuticals Inc (NASDAQ:CBST) posted its quarterly earnings data on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.54. Cubist Pharmaceuticals's quarterly revenue was up 16.2% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cubist Pharmaceuticals investors own include Intercept Pharmaceuticals (ICPT), Novavax (NVAX), Bausch Health Companies (BHC), Booking (BKNG), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY) and FLEETCOR Technologies (FLT).

Company Calendar

Last Earnings
10/21/2014
Today
6/10/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBST
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:CBST) was last updated on 6/10/2025 by MarketBeat.com Staff
From Our Partners